Stockscreener 앱 받기
17.32
1.05%
0.18
전일 마감가:
$17.14
열려 있는:
$17.04
하루 거래량:
92,996
Relative Volume:
0.43
시가총액:
$2.25B
수익:
$65.48M
순이익/손실:
$-94.46M
주가수익비율:
-23.48
EPS:
-0.7375
순현금흐름:
$-71.18M
1주 성능:
-0.69%
1개월 성능:
+17.03%
6개월 성능:
+18.79%
1년 성능:
+28.11%
1일 변동 폭
$17.03
$17.34
1주일 범위
$16.45
$17.40
52주 변동 폭
$13.05
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
Compare MESO vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
17.32 | 2.26B | 65.48M | -94.46M | -71.18M | -0.7375 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-12-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-24 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-23 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | 개시 | William Blair | Outperform |
| 2022-12-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-06 | 개시 | Piper Sandler | Overweight |
| 2021-04-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-12-22 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-12-04 | 다운그레이드 | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2020-05-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-31 | 재개 | H.C. Wainwright | Buy |
| 2018-03-22 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | 재확인 | Cantor Fitzgerald | Buy |
| 2017-08-31 | 개시 | Oppenheimer | Outperform |
| 2017-06-08 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Mesoblast Ltd Adr 주식(MESO)의 최신 뉴스
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment - Sahm
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Movi - Benzinga
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday - Sahm
Mesoblast Shares Jump 8.82% on ASX as Biotech Rebounds From Friday's Sharp Selloff Tied to State Street Filing - International Business Times Australia
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - tradingview.com
Why Mesoblast (NASDAQ:MESO) Sees NASDAQ Composite Spotlight Now? - Kalkine Media
Mesoblast Limited (ASX:MSB) Heats Up Again as Biotech Investors Watch Its Next Move - Kalkine
Mesoblast (ASX: MSB) Slips as Investors Monitor Ryoncil Growth and Product Pipeline - Kalkine
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
What Triggered Today's Move in the Mesoblast (ASX:MSB) Share Price? - Kalkine
Mesoblast (ASX:MSB) Shares Give Back Ground After a Sharp Rally - Kalkine
Daily Brief Health Care: First Wave BioPharma , NeuroSpectrum Insights, Mesoblast Ltd, Know Labs , Zoetis Inc, CTT Pharmaceutical Holdings, Oncolytics Biotech, ATAI Life Sciences NV and more - Smartkarma
Daily Brief Australia: Genesis Minerals, Perpetual Ltd, Mesoblast Ltd, BHP Group Ltd, Pacific Niugini, D3 Energy, Noble Helium and more - Smartkarma
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday - Benzinga
Why Is Mesoblast Stock Up Today? - Kalkine
Is Mesoblast (ASX:MSB) Trading Within Its 52-Week Price Range? - Kalkine
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewswire Inc.
Mesoblast reaches 300-patient enrollment in back pain trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
SK Hynix Nasdaq debut: $26.5 billion ADR listing sets record - Yahoo Finance
Mesoblast Reports Strong RYONCIL® Revenue, Exceeding Projections - Sharecafe
Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen - Barchart.com
Mesoblast (ASX:MSB): The Stem Cell Therapy Company on the Cusp of Commercial Reality - Kalkine
ASX Biotech Stocks to Watch in July 2026 - Kalkine
Mesoblast (ASX:MSB) Climbs as Biotech Bulls Return to the ASX Healthcare Trade - Kalkine
LWB1 Forecast — Price Target — Prediction for 2027 - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (LSX:A4004R) - TradingView
A4004R Forecast — Price Target — Prediction for 2027 - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (LS:A4004R) - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (NASDAQ:MESO) - TradingView
Mesoblast Limited Sponsored ADR Actuals & Estimates (GETTEX:LWB1) - TradingView
Mesoblast Ltd consensus and trial focus, shares watched on Nasdaq - Ad-hoc-news.de
ON Semiconductor, SanDisk And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - Benzinga
MESO - Finviz
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
Mesoblast LimitedDepositary Receipt (MESO) price target decreased by 14.96% to 15.33 - msn.com
Mesoblast completes enrollment in back pain therapy trial - Investing.com
Mesoblast acquires CAR technology license from Mayo Clinic - Investing.com
FDA clears Mesoblast DMD trial for Ryoncil in children - Investing.com
Mesoblast drops after Ryoncil sales data for March quarter - Seeking Alpha
MESO Ignites 10% Surge: A Biotech Spark Ignited Without a Visible Fuse - Bitget
Philip Krause details Mesoblast (NASDAQ: MESO) share and option holdings - Stock Titan
Mesoblast issues 5 million unquoted warrants as fee for US$50 million convertible note facility - MSN
Mesoblast Ltd Stock (ISIN: AU000000MSB8) Faces Pressure as Director Buys Signal Confidence Amid Anal - AD HOC NEWS
Gregory George beneficial owner at Mesoblast (OTC: MEOBF) with 22.36% stake - Stock Titan
MEOBF SEC FilingsMesoblast 10-K, 10-Q, 8-K Forms - Stock Titan
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Sahm
Earnings call transcript: Mesoblast’s strong Q1 2026 performance boosts outlook - Investing.com
Mesoblast H1 FY26 slides: first approved MSC product hits $49M - Investing.com
Mesoblast (NASDAQ: MESO) holders may resell 500,000 ADSs via warrants - Stock Titan
Mesoblast (ASX:MSB) Delivers 60% Jump in Ryoncil Sales, Strengthening Commercial Momentum - Stocks Down Under
Mesoblast Ltd Adr (MESO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mesoblast Ltd Adr 주식 (MESO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| George Gregory | Director |
Apr 10 '26 |
Buy |
1.48 |
2,324,072 |
3,439,627 |
8,324,072 |
| George Gregory | Director |
Apr 09 '26 |
Buy |
1.44 |
1,586,890 |
2,277,350 |
13,586,890 |
| George Gregory | Director |
Apr 09 '26 |
Buy |
8.59 |
1,981,890 |
17,015,467 |
13,586,890 |
| George Gregory | Director |
Apr 04 '26 |
Buy |
1.42 |
4,000,000 |
5,680,000 |
12,000,000 |
| George Gregory | Director |
Apr 10 '26 |
Buy |
1.48 |
2,324,072 |
3,439,627 |
8,324,072 |
0.86%
0.31%
자본화:
|
볼륨(24시간):